Page last updated: 2024-08-21

glycyrrhizic acid and Vascular Diseases

glycyrrhizic acid has been researched along with Vascular Diseases in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Asano, Y; Ichimura, Y; Miura, S; Nakamura, K; Saigusa, R; Sato, S; Takahashi, T; Taniguchi, T; Toyama, T; Trojanowska, M; Yamashita, T; Yoshizaki, A	1
deGottardi, A; Enseleit, F; Hürlimann, D; Lüscher, TF; Noll, G; Quaschning, T; Rossier, MF; Ruschitzka, F; Shaw, SG	1

Other Studies

2 other study(ies) available for glycyrrhizic acid and Vascular Diseases

Article	Year
Glycyrrhizin Ameliorates Fibrosis, Vasculopathy, and Inflammation in Animal Models of Systemic Sclerosis. The Journal of investigative dermatology, 2017, Volume: 137, Issue:3 Topics: Animals; Bleomycin; Disease Models, Animal; Fibroblasts; Fibrosis; Glycyrrhizic Acid; Humans; Inflammation; Mice; Mice, Inbred C57BL; Mice, Knockout; Phenotype; Scleroderma, Systemic; Skin; Th2 Cells; Transforming Growth Factor beta; Vascular Diseases	2017
Endothelin 1 type a receptor antagonism prevents vascular dysfunction and hypertension induced by 11beta-hydroxysteroid dehydrogenase inhibition: role of nitric oxide. Circulation, 2001, Jun-26, Volume: 103, Issue:25 Topics: 11-beta-Hydroxysteroid Dehydrogenases; Acetylcholine; Animals; Blood Pressure; Body Weight; Cells, Cultured; Corticosterone; Dose-Response Relationship, Drug; Endothelin Receptor Antagonists; Endothelin-1; Endothelins; Endothelium, Vascular; Gene Expression Regulation; Glycyrrhizic Acid; Heart Rate; Humans; Hydroxysteroid Dehydrogenases; Hypertension; Male; Nitrates; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Norepinephrine; Phenylpropionates; Potassium Chloride; Protein Precursors; Pyrimidines; Rats; Rats, Inbred WKY; Receptor, Endothelin A; Receptor, Endothelin B; Receptors, Endothelin; RNA, Messenger; Vascular Diseases; Vasoconstriction; Vasodilation; Vasodilator Agents; Verapamil	2001

Article

Year

Glycyrrhizin Ameliorates Fibrosis, Vasculopathy, and Inflammation in Animal Models of Systemic Sclerosis.

The Journal of investigative dermatology, 2017, Volume: 137, Issue:3

Topics: Animals; Bleomycin; Disease Models, Animal; Fibroblasts; Fibrosis; Glycyrrhizic Acid; Humans; Inflammation; Mice; Mice, Inbred C57BL; Mice, Knockout; Phenotype; Scleroderma, Systemic; Skin; Th2 Cells; Transforming Growth Factor beta; Vascular Diseases

2017

Endothelin 1 type a receptor antagonism prevents vascular dysfunction and hypertension induced by 11beta-hydroxysteroid dehydrogenase inhibition: role of nitric oxide.

Circulation, 2001, Jun-26, Volume: 103, Issue:25

Topics: 11-beta-Hydroxysteroid Dehydrogenases; Acetylcholine; Animals; Blood Pressure; Body Weight; Cells, Cultured; Corticosterone; Dose-Response Relationship, Drug; Endothelin Receptor Antagonists; Endothelin-1; Endothelins; Endothelium, Vascular; Gene Expression Regulation; Glycyrrhizic Acid; Heart Rate; Humans; Hydroxysteroid Dehydrogenases; Hypertension; Male; Nitrates; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Norepinephrine; Phenylpropionates; Potassium Chloride; Protein Precursors; Pyrimidines; Rats; Rats, Inbred WKY; Receptor, Endothelin A; Receptor, Endothelin B; Receptors, Endothelin; RNA, Messenger; Vascular Diseases; Vasoconstriction; Vasodilation; Vasodilator Agents; Verapamil

2001